Search clinical trials for: Resistance to Checkpoint Inhibitors

Total 474782 results

Jair Bar, M.D., Ph.D.

Not yet recruiting

Neo-Bio-ADAURA: A Phase II Study to Evaluate Mechanisms of Resistance to Neoadjuvant Osimertinib

Non-squamous NSCLC
BioInvent International AB
Merck Sharp & Dohme LLC

Recruiting

BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors

Hepatocellular Carcinoma | Non Small Cell Lung Cancer | Solid Tumors

Spain, Denmark, Poland, Sweden
National Cancer Institute (NCI)

Not yet recruiting

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, The PARAMMUNE Trial

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditions
aya ramadan ashmawy sarhan

Not yet recruiting

The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2
Brigham and Women's Hospital

Not yet recruiting

Drug Screening Using IMD in Bladder Cancer

Muscle Invasive Bladder Urothelial Carcinoma

United States
Chinese PLA General Hospital

Recruiting

Tumor Microenvironment in Gastric Cancer Patients Treated With Combined Immunotherapy and Chemotherapy

Gastric Cancer | Chemotherapy | Immunotherapy | Tumor Microenvironment

China
Manuel Coelho da Rocha

Not yet recruiting

Tailored vs. Empirical Helicobacter Pylori Infection Treatment

Helicobacter Pylori Infection

Portugal
Peking University

Recruiting

Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment

Liver Metastasis Colon Cancer | MSS | ctDNA Genotype | Failed From Standard Treatment

China
Dong Bing Zhao

Recruiting

Gastric Cancer Organoids in the Screening of Neoadjuvant Drugs

Gastric Cancer | Neoadjuvant Therapy | Organoid

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer (RADIOCOM)

Chemotherapeutic Toxicity | Radiotherapy; Complications | PARP Inhibitor | Immune Checkpoint Inhibitor | Trastuzumab | Breast Cancer, Familial Male | CDK4/6 Inhibitor | Pertuzumab

China
Fudan University

Not yet recruiting

Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer (PTCA199-8)

Pancreatic Cancer
James Isaacs, MD

Not yet recruiting

Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma

Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIID Melanoma

United States
Regeneron Pharmaceuticals

Not yet recruiting

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

Melanoma
Fudan University

Recruiting

Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor

Esophageal Squamous Cell Carcinoma | Oligometastatic Disease | Radiotherapy

China
Exelixis
Arcus Biosciences, Inc.

Recruiting

Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)

Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors

United States
Grit Biotechnology

Not yet recruiting

Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Squamous Cell Carcinoma

HNSCC | Adults

China
National Research Center for Hematology, Russia

Recruiting

Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL

Primary Mediastinal Lymphoma

Russian Federation
Vividion Therapeutics, Inc.

Recruiting

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors

Advanced Solid Tumors | Advanced Hematologic Tumors

United States, Australia
Affiliated Hospital of Nantong University

Recruiting

PD-1 Inhibitor Combined With Radiotherapy for Elderly ESCC

Esophageal Squamous Cell Carcinoma

China
Fundación FLS de Lucha Contra el Sida, las Enfermedades...

Recruiting

Implementation of Out-of-HOspital Administration of the Long-Acting Cabotegravir+Rilpivirine (HOLA)

HIV-1 Infection

Spain
University Medical Center Groningen
Merck Sharp & Dohme LLC

Recruiting

Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer (PAM-II)

Endometrial Cancer

Netherlands
Institut für Klinische Krebsforschung IKF GmbH...
Medizinische Hochschule Hannover, Germany, Prof. Dr. Arndt Vogel; MSD Sharp...

Not yet recruiting

Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer (TRAP-BTC)

Biliary Tract Cancer | HER2 Gene Mutation
Pamela Munster
National Cancer Institute (NCI)

Recruiting

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

BRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | ATM Gene Mutation | BRCA Mutation | Checkpoint Kinase 2 Gene Mutation

United States
Shanghai Chest Hospital

Recruiting

Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer

Esophageal Squamous Cell Carcinoma | Unresectable Locally Advanced Esophageal Cancer

China
Soonchunhyang University Hospital

Not yet recruiting

A Single-center Clinical Study to Evaluate the Safety and Efficacy of Autologous Bone Marrow-derived DCs(CellgramDC-WT1) and Immune Checkpoint Inhibitors in Patients With Metastatic Pancreatic Cancer Who Have Failed First-line or More Standard Chemotherapy (DICI_PC)

Pancreas Cancer
Qilu Pharmaceutical Co., Ltd.

Recruiting

A Study Comparing Pharmacokinetic and Safety of QL2107 and Keytruda® (Marketed in China and the United States) in Healthy Adults

Tumor

China
Xencor, Inc.

Recruiting

Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC

Nonsquamous Non-small Cell Lung Cancer

United States
Merck Sharp & Dohme LLC

Recruiting

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Non-small Cell Lung Cancer (NSCLC)

China, Australia, United States, Turkey, Chile, Taiwan, Denmark, France, Spain, Argentina, Italy, Netherlands, Thailand
Astellas Pharma Global Development, Inc.

Recruiting

A Study of ASP1012 in Adults With Solid Tumors

Solid Tumor

United States
Bristol-Myers Squibb

Recruiting

An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germany (NENI)

Resectable Non-small Cell Lung Cancer

Germany
London School of Hygiene and Tropical Medicine

Not yet recruiting

Parasite Clearance and Protection From Infection (PCPI) in Zambia

Malaria

Zambia
Melanoma and Skin Cancer Trials Limited

Not yet recruiting

Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases (BETTER)

Melanoma Brain Metastases
Northwestern University
National Cancer Institute (NCI)

Recruiting

Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma

Classic Hodgkin Lymphoma

United States
Revolution Medicines, Inc.

Recruiting

Study of RAS(ON) Inhibitor Combinations in Patients With Advanced RAS-mutated NSCLC

Non-Small Cell Lung Cancer, NSCLC | KRAS, NRAS, HRAS-mutated NSCLC | KRAS G12C-mutated Solid Tumors, Lung Cancer | Lung Cancer Stage IV, Advanced Solid Tumor, Cancer

United States
National Cancer Institute (NCI)

Not yet recruiting

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as Small Cell, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile Cancer

Squamous Cell Carcinoma of the Penis | Renal Medullary Carcinoma | Squamous Cell Carcinoma of the Bladder | Small Cell Carcinoma of the Bladder | Small Cell Carcinoma of the Urinary Tract | Squamous Cell Carcinoma of the Urinary Tract | Primary Adenocarcinoma of the Bladder | Primary Adenocarcinoma...

United States
National Cancer Institute (NCI)

Not yet recruiting

Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma

Stage II Squamous Cell Carcinoma of the Head and Neck | Stage III Squamous Cell Carcinoma of the Head and Neck | Stage IV Squamous Cell Carcinoma of the Head and Neck

United States
National Cancer Centre, Singapore
Merck Sharp & Dohme LLC; National Medical Research Council (NMRC), Singapore

Not yet recruiting

Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma (POLAR)

Refractory Peripheral T-Cell Lymphoma | Relapsed Peripheral T-Cell Lymphoma

Singapore
University of Pennsylvania

Not yet recruiting

CD40 Agonist and PD-1 Inhibitor in HNSCC

Head and Neck Squamous Cell Carcinoma
Sandoz

Not yet recruiting

A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

Metastatic NSCLC
Fudan University

Recruiting

A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer (G/GEJ cancer)

Gastric Cancer/Adenocarcinoma of Esophagogastric Junction

China
Shanghai Henlius Biotech

Recruiting

A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male Subjects

Healthy Male Volunteers

China
Queensland Institute of Medical Research
Merck Sharp & Dohme LLC; Royal Brisbane and Women's Hospital; Princess Alexandra... and other collaborators

Recruiting

T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma (TCaP)

Glioblastoma Multiforme | Astrocytoma, Grade IV

Australia
Istituto Oncologico Veneto IRCCS
MSD Italia S.r.l.

Not yet recruiting

Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study) (CHIMERA)

Pleural Mesothelioma

Italy
Sandoz

Not yet recruiting

A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma

Melanoma
Boehringer Ingelheim

Recruiting

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Lung Cancer, Non-squamous, Non-small Cell

Australia, Korea, Republic of, China, Japan, United States, Singapore, Taiwan
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer (MONAMI)

MSI | dMMR Colorectal Cancer

France
Melanoma Institute Australia
Bristol-Myers Squibb

Recruiting

Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma

Merkel Cell Carcinoma

Australia
BioNTech SE
Genmab

Recruiting

Safety and Preliminary Efficacy of BNT314 With or Without an Immune Checkpoint Inhibitor in Cancer Patients With Malignant Solid Tumors

Advanced Malignant Solid Tumor

United States, United Kingdom
Massachusetts General Hospital
Foundation Medicine

Recruiting

Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation

Melanoma | Non-small Cell Lung Cancer

United States
First Affiliated Hospital, Sun Yat-Sen University

Not yet recruiting

Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy

Papillary Renal Cell Carcinoma

Search clinical trials for: Resistance to Checkpoint Inhibitors

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations